Guggenheim Maintains Buy on Absci, Lowers Price Target to $14
Guggenheim analyst Vamil Divan maintains Absci (NASDAQ:ABSI) with a Buy and lowers the price target from $15 to $14.
Last updated: 2026-11-19 02:28:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Absci Corporation (ABSI) operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector and is listed on NASDAQ. The stock is currently priced at $8.18, with a market capitalization of $1.29B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.24 to $12.54. This page covers its latest market performance, valuation, price trends and company information.
$1.29B | |
$7.75 | |
$8.71 | |
$7.65 | |
$7.58 | |
4.79M | |
3.98M | |
-- | |
$12.54 | |
$2.24 | |
-- | |
2026-09-30 |
Absci Corporation (ABSI) last closed at $8.18 as of 2026-11-19 00:45:00, up 7.98% ($0.61) from the previous close of $7.58.
During the latest regular trading session, ABSI traded between $7.65 and $8.71, with a volume of 4.79M shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Absci Corporation (ABSI) moved from $10.80 to $8.18, representing a decline of 24.22% ($2.62).
The stock traded between $7.29 and $11.22 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 5.17 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 57.7%
ABSI is currently trading at $8.18, placing it 57.7% of the way from its 52-week low of $2.24 to its 52-week high of $12.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Employees | 140 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Absci Corporation and ABSI stock.
Guggenheim analyst Vamil Divan maintains Absci (NASDAQ:ABSI) with a Buy and lowers the price target from $15 to $14.
Needham analyst Gil Blum maintains Absci (NASDAQ:ABSI) with a Buy and raises the price target from $11 to $15.
Absci (NASDAQ:ABSI) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
Absci Corporation (ABSI) reported a quarterly loss of $0.17 per share, missing the consensus estimate of $0.15 loss by 13.33%. Revenue came in at $0.3 million, significantly missing estimates by 88.43%. The company has failed to beat consensus estimates for four consecutive quarters. Despite a 190% year-to-date gain, ABSI received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Eligible investors can buy real shares of Absci Corporation (ABSI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ABSI, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ABSI shares and USD.
ABSI Shares to USD
1.00 ABSI shares = 8.184 USD
Calculations are estimates based on the latest available price and are for reference only.